Mechanisms Underlying Visceral Hypersensitivity in Irritable Bowel Syndrome

[1]  F. Ponti,et al.  Intestinal Serotonin Release, Sensory Neuron Activation, and Abdominal Pain in Irritable Bowel Syndrome , 2011, The American Journal of Gastroenterology.

[2]  M. Forsting,et al.  Patients with irritable bowel syndrome have altered emotional modulation of neural responses to visceral stimuli. , 2010, Gastroenterology.

[3]  Kirsten Tillisch,et al.  Regional gray matter density changes in brains of patients with irritable bowel syndrome. , 2010, Gastroenterology.

[4]  G. Boeckxstaens,et al.  The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome , 2010, Gut.

[5]  N. Talley,et al.  Implications of eosinophilia in the normal duodenal biopsy – an association with allergy and functional dyspepsia , 2010, Alimentary pharmacology & therapeutics.

[6]  M. Bortolotti.  S1340 Effect of Red Pepper on Symptoms of Irritable Bowel Syndrome (IBS): A Preliminary Study , 2010 .

[7]  G. Barbara,et al.  475j Nerve Growth and Plasticity in the Colonic Mucosa of Patients With Irritable Bowel Syndrome , 2010 .

[8]  G. Barbara,et al.  Intestinal dysbiosis in irritable bowel syndrome: etiological factor or epiphenomenon? , 2010, Expert review of molecular diagnostics.

[9]  A. Garg,et al.  Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. , 2010, Gastroenterology.

[10]  L. Öhman,et al.  Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions , 2010, Nature Reviews Gastroenterology &Hepatology.

[11]  G. Barbara,et al.  Biomarkers in IBS: when will they replace symptoms for diagnosis and management? , 2009, Gut.

[12]  R. Langer,et al.  Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. , 2009, Gastroenterology.

[13]  G. Barbara,et al.  Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof‐of‐concept study , 2009, Alimentary pharmacology & therapeutics.

[14]  P. Moayyedi,et al.  Efficacy of 5-HT3 Antagonists and 5-HT4 Agonists in Irritable Bowel Syndrome: Systematic Review and Meta-Analysis , 2009, The American Journal of Gastroenterology.

[15]  K. Garsed,et al.  Postinfectious irritable bowel syndrome. , 2009, Gastroenterology.

[16]  J. Persson,et al.  TRPV1-expressing sensory fibres and IBS: links with immune function , 2009, Gut.

[17]  D. Santini,et al.  Mucosal Immune Activation in Irritable Bowel Syndrome: Gender-Dependence and Association With Digestive Symptoms , 2009, The American Journal of Gastroenterology.

[18]  G. Barbara,et al.  What is the effect of inflammation on intestinal function? , 2008, Inflammatory bowel diseases.

[19]  J. Galmiche,et al.  Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators , 2008, Gut.

[20]  D. Grundy.  5-HT system in the gut: roles in the regulation of visceral sensitivity and motor functions. , 2008, European review for medical and pharmacological sciences.

[21]  A. Zinsmeister,et al.  Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[22]  N. Vergnolle.  Postinflammatory visceral sensitivity and pain mechanisms , 2008, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[23]  A. Masclee,et al.  Symptom severity but not psychopathology predicts visceral hypersensitivity in irritable bowel syndrome. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[24]  P. Anand,et al.  Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain , 2008, Gut.

[25]  Hinrich W. H. Göhlmann,et al.  Alterations in mucosal immunity identified in the colon of patients with irritable bowel syndrome. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[26]  A. Szallasi,et al.  Capsaicin (TRPV1 Agonist) Therapy for Pain Relief: Farewell or Revival? , 2008, The Clinical journal of pain.

[27]  T. Dinan,et al.  Mucosal cytokine imbalance in irritable bowel syndrome , 2008, Scandinavian journal of gastroenterology.

[28]  B. Spiegel,et al.  Functional GI disorders: from animal models to drug development , 2007, Gut.

[29]  Jan Tack,et al.  Altered rectal perception in irritable bowel syndrome is associated with symptom severity. , 2007, Gastroenterology.

[30]  J. Furness,et al.  Novel therapeutic targets for enteric nervous system disorders. , 2007, Trends in pharmacological sciences.

[31]  R. Spiller.  Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5‐HT signalling and metabolism in human disease , 2007, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[32]  B. Meerveld.  Importance of 5-hydroxytryptamine receptors on intestinal afferents in the regulation of visceral sensitivity. , 2007 .

[33]  M. Camilleri,et al.  Intestinal permeability and irritable bowel syndrome , 2007, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[34]  M. Steinhoff,et al.  Role for protease activity in visceral pain in irritable bowel syndrome. , 2007, The Journal of clinical investigation.

[35]  E. Björnsson,et al.  Lipid-induced colonic hypersensitivity in the irritable bowel syndrome: the role of bowel habit, sex, and psychologic factors. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[36]  M. Camilleri,et al.  Symptomatic overlap between irritable bowel syndrome and microscopic colitis , 2007 .

[37]  R. Spiller,et al.  Mechanisms of hypersensitivity in IBS and functional disorders , 2007, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[38]  E. Björnsson,et al.  Nutrient‐dependent enhancement of rectal sensitivity in irritable bowel syndrome (IBS) , 2007 .

[39]  G. Locke,et al.  Gender, age, society, culture, and the patient's perspective in the functional gastrointestinal disorders. , 2006, Gastroenterology.

[40]  G. Barbara,et al.  Functional gastrointestinal disorders and mast cells: implications for therapy , 2006, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[41]  J. Park,et al.  Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome , 2006, Journal of gastroenterology and hepatology.

[42]  G. Gebhart,et al.  The Mechanosensitivity of Mouse Colon Afferent Fibers and Their Sensitization by Inflammatory Mediators Require Transient Receptor Potential Vanilloid 1 and Acid-Sensing Ion Channel 3 , 2005, The Journal of Neuroscience.

[43]  A. Mangel,et al.  Prevalence and demographics of irritable bowel syndrome: results from a large web‐based survey , 2005, Alimentary pharmacology & therapeutics.

[44]  M. Tonini,et al.  5‐Hydroxytryptamine effects in the gut: the 3, 4, and 7 receptors , 2005, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[45]  L. Chang,et al.  Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact , 2005, Alimentary pharmacology & therapeutics.

[46]  Wang Lh,et al.  Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis , 2004 .

[47]  G. Barbara,et al.  New pathophysiological mechanisms in irritable bowel syndrome , 2004, Alimentary pharmacology & therapeutics.

[48]  M. Crowell,et al.  Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. , 2004, Gastroenterology.

[49]  P. Geppetti,et al.  Activation and sensitisation of the vanilloid receptor: role in gastrointestinal inflammation and function , 2004, British journal of pharmacology.

[50]  D. Santini,et al.  Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. , 2004, Gastroenterology.

[51]  M. Bortolotti,et al.  Dilated intercellular spaces as a marker of oesophageal damage: comparative results in gastro‐oesophageal reflux disease with or without bile reflux , 2003, Alimentary pharmacology & therapeutics.

[52]  N. Read,et al.  Increased rectal mucosal expression of interleukin 1β in recently acquired post-infectious irritable bowel syndrome , 2003, Gut.

[53]  P. Anand,et al.  Sensory fibres expressing capsaicin receptor TRPV1 in patients with rectal hypersensitivity and faecal urgency , 2003, The Lancet.

[54]  B. Naliboff,et al.  Irritable Bowel Syndrome Patients Show Enhanced Modulation of Visceral Perception by Auditory Stress , 2003, American Journal of Gastroenterology.

[55]  D. Drossman,et al.  AGA technical review on irritable bowel syndrome. , 2002, Gastroenterology.

[56]  L. Blackshaw,et al.  Excitation of rat colonic afferent fibres by 5‐HT3 receptors , 2002, The Journal of physiology.

[57]  M. Kreis,et al.  Cosensitivity of vagal mucosal afferents to histamine and 5-HT in the rat jejunum. , 2002, American journal of physiology. Gastrointestinal and liver physiology.

[58]  P. Schoenfeld,et al.  The epidemiology of irritable bowel syndrome in North America: a systematic review. , 2002 .

[59]  G. Barbara,et al.  A role for inflammation in irritable bowel syndrome? , 2002, Gut.

[60]  Wangxue Chen,et al.  Activation of the mucosal immune system in irritable bowel syndrome. , 2002, Gastroenterology.

[61]  F. Shanahan,et al.  Celiac disease and irritable bowel-type symptoms. , 2002 .

[62]  H. El‐Serag,et al.  Health‐related quality of life among persons with irritable bowel syndrome: a systematic review , 2002, Alimentary pharmacology & therapeutics.

[63]  Clifford Goodman,et al.  The burden of selected digestive diseases in the United States. , 2002, Gastroenterology.

[64]  P. Poitras,et al.  Evolution of Visceral Sensitivity in Patients with Irritable Bowel Syndrome , 2002, Digestive Diseases and Sciences.

[65]  E. Björnsson,et al.  Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors , 2002, American Journal of Gastroenterology.

[66]  G. Barbara,et al.  Role of immunologic factors and cyclooxygenase 2 in persistent postinfective enteric muscle dysfunction in mice. , 2001, Gastroenterology.

[67]  E. Bjornsson,et al.  An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome , 2001, Gut.

[68]  R. Spiller,et al.  Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acuteCampylobacter enteritis and in post-dysenteric irritable bowel syndrome , 2000, Gut.

[69]  A. Kilbourne,et al.  The impact of irritable bowel syndrome on health-related quality of life. , 2000, Gastroenterology.

[70]  R. Kessler,et al.  Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. , 2000, Gastroenterology.

[71]  D. Grundy,et al.  The 5-HT3 receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinalc-fos expression in the anaesthetised rat , 2000, Gut.

[72]  M. Camilleri,et al.  Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial , 2000, The Lancet.

[73]  B. Naliboff,et al.  Differences in somatic perception in female patients with irritable bowel syndrome with and without fibromyalgia , 2000, PAIN®.

[74]  K W Heaton,et al.  Irritable bowel syndrome in general practice: prevalence, characteristics, and referral , 2000, Gut.

[75]  G. Barbara,et al.  Neutral endopeptidase (EC 3.4.24.11) terminates colitis by degrading substance P. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[76]  W. Whitehead,et al.  Is rectal pain sensitivity a biological marker for irritable bowel syndrome: psychological influences on pain perception. , 1998, Gastroenterology.

[77]  D. Grundy,et al.  Sensitivity to 5‐hydroxytryptamine in different afferent subpopulations within mesenteric nerves supplying the rat jejunum , 1998, The Journal of physiology.

[78]  V. Théodorou,et al.  Stress‐induced visceral hypersensitivity to rectal distension in rats: role of CRF and mast cells , 1997, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[79]  G. Barbara,et al.  Persistent intestinal neuromuscular dysfunction after acute nematode infection in mice. , 1997, Gastroenterology.

[80]  J. Malagelada,et al.  Attention and distraction: effects on gut perception. , 1997, Gastroenterology.

[81]  L Bueno,et al.  Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations. , 1997, Gastroenterology.

[82]  S. Collins.  The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders. , 1996, Gastroenterology.

[83]  R. Heading,et al.  Heightened visceral sensation in functional gastrointestinal disease is not site-specific , 1995, Digestive Diseases and Sciences.

[84]  E A Mayer,et al.  Altered rectal perception is a biological marker of patients with irritable bowel syndrome. , 1995, Gastroenterology.

[85]  D. Drossman,et al.  Functional Bowel Disorders , 1995, The American Journal of Gastroenterology.

[86]  A. Zinsmeister,et al.  Visceral perception in irritable bowel syndrome , 1995, Digestive Diseases and Sciences.

[87]  J. Malagelada,et al.  Selective dysfunction of mechanosensitive intestinal afferents in irritable bowel syndrome. , 1995, Gastroenterology.

[88]  E A Mayer,et al.  Basic and clinical aspects of visceral hyperalgesia. , 1994, Gastroenterology.

[89]  W. Whitehead,et al.  Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction. , 1992, Gut.

[90]  P. Holzer.  Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory neurons. , 1991, Pharmacological reviews.

[91]  W. Whitehead,et al.  Tolerance for rectosigmoid distention in irritable bowel syndrome. , 1990, Gastroenterology.

[92]  I. Cook,et al.  Patients with irritable bowel syndrome have greater pain tolerance than normal subjects. , 1987, Gastroenterology.

[93]  P. Whorwell,et al.  Symptoms of irritable bowel syndrome in ulcerative colitis in remission , 1983, Gut.

[94]  J. Ritchie.  Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome 1 , 1973, Gut.

[95]  S. Maxion-Bergemann,et al.  Costs of irritable bowel syndrome in the UK and US , 2012, PharmacoEconomics.

[96]  B. Chizh,et al.  Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway. , 2009, Drug discovery today.

[97]  Hinrich W. H. Göhlmann,et al.  Alterations in expression of p11 and SERT in mucosal biopsy specimens of patients with irritable bowel syndrome. , 2007, Gastroenterology.

[98]  G. Barbara,et al.  Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. , 2007, Gastroenterology.

[99]  J. Tack,et al.  REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY The Serotonin Signaling System: From Basic Understanding To Drug Development for Functional GI Disorders , 2007 .